Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy

NCT04263610 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Dimethyl fumarate (DMF) standard scheme
DRUG: Dimethyl fumarate (DMF) simplified scheme
DRUG: Tildrakizumab

Sponsor

Almirall, S.A.